Stuck NASA astronauts welcome SpaceX capsule that'll bring them home next year

rescue mission

SpaceX's Dragon capsule docked onto the ISS and will return to Earth in February. Photo via SpaceX

The two astronauts stuck at the International Space Station since June welcomed their new ride home with Sunday’s arrival of a SpaceX capsule.

SpaceX launched the rescue mission on Saturday with a downsized crew of two astronauts and two empty seats reserved for Butch Wilmore and Suni Williams, who will return next year. The Dragon capsule docked in darkness as the two craft soared 265 miles (426 kilometers) above Botswana.

NASA switched Wilmore and Williams to SpaceX following concerns over the safety of their Boeing Starliner capsule. It was the first Starliner test flight with a crew, and NASA decided the thruster failures and helium leaks that cropped up after liftoff were too serious and poorly understood to risk the test pilots’ return. So Starliner returned to Earth empty earlier this month.

The Dragon carrying NASA’s Nick Hague and the Russian Space Agency’s Alexander Gorbunov will remain at the space station until February, turning what should have been a weeklong trip for Wilmore and Williams into a mission lasting more than eight months.

Two NASA astronauts were pulled from the mission to make room for Wilmore and Williams on the return leg.

“I just want to say welcome to our new compadres,” Williams, the space station commander, said once Hague and Gorbunov floated inside and were embraced by the nine astronauts awaiting them.

Hague said it was a smooth flight up. “Coming through the hatch and seeing all the smiles, and as much as I've laughed and cried in the last 10 minutes, I know it's going to be an amazing expedition," he said.

NASA likes to replace its station crews every six months or so. SpaceX has provided the taxi service since the company’s first astronaut flight in 2020. NASA also hired Boeing for ferry flights after the space shuttles were retired, but flawed software and other Starliner issues led to years of delays and more than $1 billion in repairs.

Starliner inspections are underway at NASA’s Kennedy Space Center, with post-flight reviews of data set to begin this week.

“We’re a long way from saying, ‘Hey, we’re writing off Boeing,’” NASA’s associate administrator Jim Free said at a pre-launch briefing.

The arrival of two fresh astronauts means the four who have been up there since March can now return to Earth in their own SpaceX capsule in just over a week, bringing the station's crew size back down to the normal seven. Their stay was extended a month because of the Starliner turmoil.

Although Saturday’s liftoff went well, SpaceX said the rocket’s spent upper stage ended up outside its targeted impact zone in the Pacific because of a bad engine firing. The company has halted all Falcon launches until it figures out what went wrong.was extended a month because of the Starliner turmoil.

From Your Site Articles
A new pharmacy startup has officially launched in Houston. Photo courtesy of Capsule

Digital pharmacy launches in Houston to address access with same-day delivery

launching in HOU

A health tech company has officially launched locally to serve as a digital pharmacy platform. The company is aiming to simplify the process for customers.

Capsule has launched in Houston to address access-challenged pharmacy deserts as well as allow for discreet delivery of frequently stigmatized medications. The company also prioritizes better communications than standard pharmacy service.

"Capsule's mission has always been to build a pharmacy that works for everyone," says Eric Kinariwala, founder and CEO of Capsule, in a news release. "We believe that the core pharmacy experience is fundamentally broken for the hundreds of millions of Americans who take medication regularly, so we set out to rebuild that experience from the inside out."

Capsule's custom software prevents common issues out-of-stock medications, long wait times, and lack of price transparency, as well as improves communications. Customers can sign up for the service — which includes same-day delivery within all of Harris County and parts of Chambers, Fort Bend, Galveston, and Montgomery counties — and have their physician send their prescriptions to Capsule. The company accepts all major insurance plans, including Medicare and Medicaid.

One problem that Capsule is attempting to solve is access to pharmaceuticals. According to the release, half of prescriptions in America go unfilled resulting in $300 billion in additional healthcare costs. One factor contributing to this problem is access.

"We know that there is a direct link between proximity to a pharmacy and prescription fill rates," Kinariwala says. "And the consequences of failing to fill vital prescriptions can be dire. Capsule is a part of the solution."

In Houston, pharmacy deserts disproportionately affect minorities. Over 40 percent of Hispanic residents and 70 percent of Black residents live a mile or more away from a pharmacy. According to USA Rx data, Harris County has 1.39 pharmacies per 10,000 residents, which is below the national average of 2.4.

"Capsule's long-term ambition is to create a hub where consumers can access all of their healthcare needs in a single, simple, holistic place," says Kinariwala. "We're doing that in a way that brings together everybody in healthcare versus trying to own all of those things ourselves. Just like you buy a cell phone and choose apps, people will be able to access Capsule's digital pharmacy, as well as a best-in-class curated set of products and services to meet all of their healthcare needs from within a single app."

Eric Kinariwala is the founder and CEO of Capsule. Photo courtesy of Capsule

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

CPRIT CEO: Houston’s $2B in funding is transforming cancer research and prevention

fighting cancer

With its plethora of prestigious health care organizations like the University of Texas MD Anderson Cancer Center, UTHealth Houston, and the Baylor College of Medicine, Houston sits at the heart of cancer research and prevention in Texas.

Of course, it takes piles of cash to support Houston’s status as the state’s hub for cancer research and prevention. Much of that money comes from the Cancer Prevention and Research Institute of Texas (CPRIT).

Data supplied by CPRIT shows organizations in Harris County gained $2.3 billion in institute funding from 2009 through 2025, or nearly $145 million per year. That represents almost 60 percent of the roughly $4 billion that CPRIT has granted to Texas institutions over a 16-year period.

“The life sciences ecosystem that has developed and changed in Houston is phenomenal,” Kristen Doyle, who became the agency’s CEO in July 2024, tells InnovationMap. “In the next decade, we will look back and see a great transformation.”

That ecosystem includes more than 1,100 life sciences and biotech companies, according to the Greater Houston Partnership.

Houston plays critical role in clinical trials

Texas voters approved the creation of CPRIT in 2007. Twelve years later, voters agreed to earmark an extra $3 billion for CPRIT, bringing the state agency’s total investment in cancer research and prevention to $6 billion.

To date, CPRIT money has gone toward recruiting 344 cancer researchers to Texas (mainly to Houston) and has supported cancer prevention services for millions of Texans in the state’s 254 counties. CPRIT funding has also helped establish, expand, or relocate 25 cancer-focused companies. In Houston, MD Anderson ranks as the No. 1 recipient of CPRIT funding.

Regarding cancer research, Doyle says Houston plays a critical role in clinical trials.

“[Clinical trials are] something that CPRIT has focused on more and more. Brilliant discoveries are crucial to this whole equation of solving the cancer problem,” Doyle says. “But if those brilliant ideas stay in the labs, then we’ve all failed.”

Researchers conduct more clinical trials in Houston than anywhere else in the U.S., the Greater Houston Partnership says.

Doyle, a 20-year survivor of leukemia, notes that a minority of eligible patients participate in clinical trials for cancer treatments, “and that’s one of the reasons that it takes so long to get a promising drug to market.”

An estimated 7 percent of cancer patients sign up for clinical trials, according to a study published in 2024 in the Journal of Clinical Oncology.

MD Anderson takes on cancer prevention

Doyle also notes that Houston is leading the charge in cancer prevention.

“We get some national recognition for programs that have been developed in Houston that then can be replicated in other parts of the country,” she says.

Much of the work in Houston focusing on cancer prevention takes place at MD Anderson. The hospital reports that it has received more than $725 million from the CPRIT since 2007, representing approximately 18 percent of CPRIT’s total awards.

“These efforts can have profound impact on the lives of patients and their families, and this funding ensures our exemplary clinicians and scientists can continue working together to drive breakthroughs that advance our mission to end cancer,” Dr. Giulio Draetta, chief scientific officer at MD Anderson, said in a November news release, following the most recent CPRIT award for the hospital totalling more than $29 million.

CPRIT funding for Houston institutions supplements the more than $4.5 billion in federal funding for health and life sciences research and innovations that the Houston area received from 2020 to 2024, according to the Greater Houston Partnership.

“We are curing cancer every single day,” Doyle says of CPRIT. “Every step that we are taking — whether that’s funding great ideas or funding the clinical trials that are bringing promising drugs to Texas and to the world — we are making a difference.”

Houston energy tech co. breaks ground on low-cost hydrogen pilot plant

Coming Soon

Houston’s Lummus Technology and Advanced Ionics have broken ground on their hydrogen pilot plant at Lummus’ R&D facility in Pasadena, Texas.

The plant will support Advanced Ionics’ cutting-edge electrolyzer technology, which aims to deliver high-efficiency hydrogen production with reduced energy requirements.

“By demonstrating Advanced Ionics’ technology at our state-of-the-art R&D facility, we are leveraging the expertise of our scientists and R&D team, plus our proven track record of developing breakthrough technologies,” Leon de Bruyn, president and CEO of Lummus, said in a news release. “This will help us accelerate commercialization of the technology and deliver scalable, cost-effective and sustainable green hydrogen solutions to our customers.”

Advanced Ionics is a Milwaukee-based low-cost green hydrogen technology provider. Its electrolyzer converts process and waste heat into green hydrogen for less than a dollar per kilogram, according to the company. The platform's users include industrial hydrogen producers looking to optimize sustainability at an affordable cost.

Lummus, a global energy technology company, will operate the Advanced Ionics electrolyzer and manage the balance of plant systems.

In 2024, Lummus and Advanced Ionics established their partnership to help advance the production of cost-effective and sustainable hydrogen technology. Lummus Venture Capital also invested an undisclosed amount into Advanced Ionics at the time.

“Our collaboration with Lummus demonstrates the power of partnerships in driving the energy transition forward,” Ignacio Bincaz, CEO of Advanced Ionics, added in the news release. “Lummus serves as a launchpad for technologies like ours, enabling us to validate performance and integration under real-world conditions. This milestone proves that green hydrogen can be practical and economically viable, and it marks another key step toward commercial deployment.”

---

This article originally appeared on EnergyCapitalHTX.com.

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.

View All Listings